Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.

ABSTRACT: Brain atrophy occurs at a faster rate in patients with multiple sclerosis (MS) than in healthy individuals. In three randomized, controlled, phase III trials, fingolimod reduced the annual rate of brain volume loss (BVL) in patients with relapsing MS (RMS) by approximately one-third relative to that in individuals receiving placebo or intramuscular interferon beta-1a. Analysis of brain volume changes during study extensions has shown that this reduced rate of BVL is sustained in patients with RMS receiving fingolimod continuously. Subgroup analyses of the core phase III and extension studies have shown that reductions in the rate of BVL are observed irrespective of levels of inflammatory lesion activity seen by magnetic resonance imaging at baseline and on study; levels of disability at ba

SUBMITTER: De Stefano N 

PROVIDER: S-EPMC5374177 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature